Liver disease, Biliary atresia
IPSEYIpsenCatalyst overview
Research summary
This catalyst tracks a Phase 3 update for Odevixibat (ileal bile acid transport inhibitor) in Liver disease, Biliary atresia. The expected timing is based on the latest available company guidance and may change.
07/30/26:- BOLD Ph3 biliary atresia trial missed primary endpoint; no new safety signals.
Verification
Confirm timing and program details against the company announcement or filing.